-
EP4057989
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4057989
| EP4057989 - 1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)METHOXY)-7-METHOXYISOQUINOLINE-6-CARBOXAMIDE COMBINATIONS AND ORAL DOSAGE FORMS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 19.08.2022 Database last updated on 02.11.2024 | |
| Former | The international publication has been made Status updated on 21.05.2021 | ||
| Former | unknown Status updated on 27.11.2020 | Most recent event Tooltip | 01.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US | [2023/14] |
| Former [2022/38] | For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US | Inventor(s) | 01 /
HUTCHINS, Allan Joseph c/o Pfizer Inc. 445 Eastern Point Road Bldg. 98 Groton, Connecticut 06340 / US | 02 /
MACDONALD, Bruce Clinton c/o Pfizer Inc. 445 Eastern Point Road Bldg. 98 Groton, Connecticut 06340 / US | 03 /
RAO, Vikram Rama c/o Pfizer Inc. 610 Main Street Cambridge, Massachusetts 02139 / US | 04 /
TANG, Degui c/o Pfizer Inc. 445 Eastern Point Road Bldg. 98 Groton, Connecticut 06340 / US | 05 /
YU, Weili c/o Pfizer Inc. 445 Eastern Point Road Bldg. 98 Groton, Connecticut 06340 / US | [2022/38] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2022/38] | Application number, filing date | 20808525.8 | 11.11.2020 | [2022/38] | WO2020IB60627 | Priority number, date | US201962935450P | 14.11.2019 Original published format: US 201962935450 P | US202063024174P | 13.05.2020 Original published format: US 202063024174 P | [2022/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021094953 | Date: | 20.05.2021 | Language: | EN | [2021/20] | Type: | A1 Application with search report | No.: | EP4057989 | Date: | 21.09.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.05.2021 takes the place of the publication of the European patent application. | [2022/38] | Search report(s) | International search report - published on: | EP | 20.05.2021 | Classification | IPC: | A61K9/00, A61K9/20, A61K31/4439, A61P17/10, A61P19/02, A61K31/519, A61K45/06, A61K9/28 | [2022/38] | CPC: |
A61K9/0004 (EP,IL,KR,US);
A61K31/4725 (EP,IL,KR,US);
A61K9/2054 (KR,US);
A61K31/519 (EP,IL,KR,US);
A61K9/2009 (US);
A61K9/2018 (EP,IL,US);
A61K9/2027 (US);
A61K9/2031 (US);
A61K9/2853 (US);
A61K9/2866 (EP,IL,US);
A61P17/10 (EP,IL);
A61P19/02 (EP,IL,KR);
| C-Set: |
A61K31/4725, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/38] | Title | German: | 1-(((2S,3S,4S)-3-ETHYL-4-FLUOR-5-OXOPYRROLIDIN-2-YL)METHOXY)-7-METHOXYISOCHINOLIN-6-CARBOXAMID KOMBINATIONEN UND ORALE DOSIERUNGSFORMEN | [2022/38] | English: | 1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)METHOXY)-7-METHOXYISOQUINOLINE-6-CARBOXAMIDE COMBINATIONS AND ORAL DOSAGE FORMS | [2022/38] | French: | COMBINAISONS DE 1-(((2S,3S,4S)-3-ÉTHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)MÉTHOXY)-7-MÉTHOXYISOQUINOLÉINE-6-CARBOXAMIDE ET FORMES PHARMACEUTIQUES ORALES | [2022/38] | Entry into regional phase | 14.06.2022 | National basic fee paid | 14.06.2022 | Designation fee(s) paid | 14.06.2022 | Examination fee paid | Examination procedure | 13.05.2022 | Amendment by applicant (claims and/or description) | 14.06.2022 | Examination requested [2022/38] | 14.06.2022 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 30.11.2022 | Renewal fee patent year 03 | 30.11.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IAY]WO2014147526 (PFIZER [US]) [I] 1 * examples 2,3 * [A] 2-7,11-16[Y] 1; | [YA]US2019092750 (LEE KATHERINE LIN [US], et al) [Y] 1 * claims 1,5,8,9 * * the whole document * [A] 2-7,11-16; | [IAY] - Pfizer, "A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE", (20170808), pages 1 - 150, URL: https://clinicaltrials.gov/ProvidedDocs/00/NCT02996500/Prot_001.pdf, (20210121), XP055767751 [I] 8-10 * page 20, paragraph 3 * * the whole document * [A] 2-7,11-16 [Y] 1 | by applicant | US3247066 | US3952741 | US4519801 | EP0357369 | US5358502 | US5612059 | US5698220 | WO0142246 | WO02096909 | WO03048162 | WO2005053653 | US2005181062 | US2005186285 | US2007248671 | US2008199527 | WO2015083028 | WO2015150995 | US9937181 | - FIRESTEINMCLNNES, Immunity, (20170221), vol. 46, no. 2, pages 183 - 196 | - N. SUZUKIT. SAITO, Trends in Immunology, (20060000), vol. 27, page 566 | - T. W. KIMK. STASCHKEK. BULEKJ. YAOK. PETERSK.-H. OHY. VANDENBURGH. XIAOW. QIANT. HAMILTON, Journal of Experimental Medicine, (20070000), vol. 204, page 1025 | - J. FRACZEKT. W. KIMH. XIAOJ. YAOQ. WENY. LIJ.-L. CASANOVAJ. PRYJMAX. LI, Journal of Biological Chemistry, (20080000), vol. 283, page 31697 | - M. KOZICZAK-HOLBROA. LITTLEWOOD-EVANSB. POLLINGERJ. KOVARIKJ. DAWSONG. ZENKEC. BURKHARTM. MULLERH. GRAM, Arthritis & Rheumatism, (20090000), vol. 60, page 1661 | - M. HERNANDEZJ. F. BASTIAN, Current Allergy and Asthma Reports, (20060000), vol. 6, page 468 | - E. LAVINER. SOMECHJ. Y. ZHANGA. PUELX. BOSSUYTC. PICARDJ. L. CASANOVAC. M. ROIFMAN, Journal of Allergy and Clinical Immunology, (20070000), vol. 120, page 948 | - M. REKHTERK. STASCHKET. ESTRIDGEP. RUTHERFORDN. JACKSOND. GIFFORD-MOOREP. FOXWORTHYC. REIDYX.-D. HUANGM. KALBFLEISCH, Biochemical and Biophysical Research Communications, (20080000), vol. 367, page 642 | - O'NEILL, L. A., "Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases", Curr Opin Pharmacol, (20030000), vol. 3, no. 4, page 396 | - KANZLER, H et al., "Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists", Nature Medicine, (20070000), vol. 13, page 552 | - WAGNER, H., "Endogenous TLR ligands and autoimmunity", Advances in Immunol, (20060000), vol. 91, page 159 | - NGO, V. N. et al., "Oncogenically active MyD88 mutations in human lymphoma", Nature, (20110000), vol. 470, doi:10.1038/nature09671, page 115, XP055141842 DOI: http://dx.doi.org/10.1038/nature09671 | - Org. Processs Res. Dev., (20180000), vol. 22, pages 1835 - 1845 | - THORARENSEN et al., J. Med. Chem., (20170000), vol. 60, pages 1971 - 1993 | - Remington: The Science and Practice of Pharmacy, (20060000), pages 950 - 1 | - C.-M. ANDERSSONA. HALLBERGT. HOEGBERG, "Advances in the development of pharmaceutical antioxidants", Advances in Drug Research, (19960000), vol. 28, pages 65 - 180 | - HERBIG et al., J. Controlled Release, (19950000), vol. 35, pages 127 - 136 | - "Impurities in Drug Products", WATERMAN et al., Handbook of Isolation and Characterization of Impurities in Pharmaceuticals, (20030000), pages 75 - 85 | - "Colorimetric determination of hydrogen peroxide", G. M. EISENBERG, Ind. Eng. Chem. (Anal. Ed., (19430000), vol. 15, pages 327 - 328 | - M. ASHRAF-KHORASSANI et al., "Purification of pharmaceutical excipients with supercritical fluid extraction", Pharm. Dev. Tech., (20050000), vol. 10, pages 1 - 10 | - YOSHINO, Capsugel Symposia Series; Current Status on Targeted Drug Delivery to the Gastrointestinal Tract, (19930000), pages 185 - 190 | - KHOSLADAVIS, Int. J. Pharmaceut., vol. 62, no. 1990, pages R9 - R11 | US19930023227 |